Trial Profile
A randomized, multicenter Phase I clinicaltrial of single-dose GB221 (Herceptin) in HER-2 positive breast cancer patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications HER2 positive breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genor Biopharma
- 19 Sep 2019 Status changed from recruiting to completed, according to a Genor Biopharma Media Release.
- 19 Sep 2019 Results presented in a Genor Biopharma Media Release.
- 03 May 2016 New trial record